Your AI-Trained Oncology Knowledge Connection!
Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com
The combination of dabrafenib and trametinib plus navitoclax generated responses and met the co-primary end point for complete response rate vs historical controls in patients with BRAF V600–mutant metastatic melanoma.
Treatment with the investigational gamma secretase inhibitor nirogacestat allowed patients with progressing desmoid tumors to experience a significant and clinically meaningful reduction in several aspects of disease-related pain when compared with placebo.
Subcutaneous delivery of fixed-dose adjuvant pertuzumab plus trastuzumab proved to have favorable tolerability, with a safety profile consistent with that seen with intravenous delivery of the regimen in patients with HER2-positive breast cancer.
Tycel Phillips, MD, discusses the significance of the FDA approval for epcoritamab in diffuse large B-cell lymphoma, key data from the EPCORE NHL-1 trial that support this approval, and how the approval of epcoritamab signals the expanding role of bispecific antibodies in this patient population.
Suzanne B. Coopey, MD, FACS, discusses the de-escalation of axillary lymph node surgery, shifts in the use of radiation oncology, and changes in the treatment paradigm for HER2-positive breast cancer.
Christie J. Hilton, DO, details the evolving role of trastuzumab deruxtecan in HER2-positive breast cancer and the potential to de-escalate therapy in early-stage disease.
Gastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in appendiceal cancer, and the need for anticipatory, multidisciplinary guidance in clinical practice.
John V. Heymach, MD, PhD, expands on the efficacy of perioperative durvalumab in the AEGAN trial, the significance of this unique approach for the non–small cell lung cancer treatment paradigm, and future research examining opportunities to build on or intensify the benefit achieved with this regimen.
Mitchell E. Horwitz, MD, expands on key efficacy and safety data supporting the FDA approval of omidubicel, the significance of this decision for the blood cancer treatment paradigm, and the need for continued investigation of the agent in non-malignant disease and other patient subgroups.
Fred Saad, MD, FRCS, expands on the relationship between PSA responses and survival outcomes in the ARASENS trial, explained the use of 0.2 ng/mL as a standard cut off for undetectable PSA within this exploratory analysis, and discussed how this study elucidates future directions for research with triplet regimens in mHSPC.
Roger Li, MD, discusses how the synergistic mechanism of pembrolizumab plus CG0070 could address unmet needs in BCG-unresponsive NMIBC, safety and efficacy data for the combination from the CORE-001 trial, and how those data support planned research efforts for CG0070 in this space.
Chan Cheah, MBBS, FRACP, FRCPA, DMSc, discusses key safety and efficacy data from the EPCORE NHL-1 trial that may serve to support the approval of epcoritamab in patients with relapsed or refractory large B-cell lymphoma, and highlighted ongoing research efforts seeking to further move the needle forward in this disease.
Lida A. Mina, MD, discusses the evolving role of ADCs across breast cancer subtypes, current data on the use of CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer, and the increased use of genomic testing and NGS to improve the sequencing of agents in triple-negative breast cancer.
Benjamin H. Lowentritt, MD, FACS, highlights key findings from the retrospective study of second-generation ARSI use in patients with metastatic castration-sensitive prostate cancer treated in clinic and discusses several directions for future analyses of real-world outcomes in prostate cancer.
Jayesh Desai, MBBS, FRACP, reports prior phase 1 data on the use of divarasib monotherapy in KRAS G12C–mutated CRC and early efficacy, safety, and presents pharmacokinetic data from the use of divarasib plus cetuximab from a phase 1 trial.
Thomas M. Habermann, MD, expands on previous data that supported the initial accelerated approval of ibrutinib in marginal zone lymphoma and mantle cell lymphoma, phase 3 data leading to the agent’s voluntary withdrawal, and investigations of ibrutinib and other BTK inhibitors that could significantly change the treatment landscape in mantle cell lymphoma and marginal zone lymphoma.
Proof of mechanism and safety has been established for the first-in-class bisialidase and Fc fusion protein E-602 in advanced solid tumors, supporting its continued investigation and viability of harnessing glycan-mediated immune regulation as a novel therapeutic approach in this population.
Alexander Putnam Cole, MD, discusses the importance of investigating racial and ethnic disparities in prostate cancer outcomes, key data from a comparison of cancer-specific survival according to race and treatment modality, and how these results could better inform efforts to improve access to, and quality of, patient care in this disease.
The frontline combination of ribociclib and letrozole significantly prolonged overall survival over letrozole alone in a subset of patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy, according to data from an exploratory analysis of the phase 3 MONALEESA-2 trial.
Administration of trilaciclib followed by sacituzumab govitecan showed early signals of efficacy and may reduce the incidence of adverse effects in heavily pretreated patients with unresectable locally advanced or metastatic triple-negative breast cancer, according to preliminary results from a phase 2 study.
Ahmed O. Kaseb, MD, discusses how the previous approval of atezolizumab and bevacizumab in hepatocellular carcinoma provided the impetus for the IMBrave050 study, how data from this study could support the regimen’s approval in the adjuvant setting, and how this approval could substantially improve the treatment landscape for early-stage disease.
Shilpa Gupta, MD, discussed the significance of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer, updated data on the use of avelumab maintenance therapy following first-line chemotherapy in this population, and how this research could better inform patient-provider conversations about this option in the clinic.
Attaya Suvannasankha, MD, discusses the unique mechanism of action of REGN5459, the early efficacy and safety of the immunotherapy in heavily pretreated patients with relapsed/refractory multiple myeloma, and opportunities for further exploration.
The TKI anlotinib plus the PARP inhibitor niraparib continued to provide overall survival benefit with an acceptable safety profile when given to patients with platinum-resistant recurrent ovarian cancer.
Aristotelis Bamias, MD, discusses the efficacy and safety data from the final OS analysis of the IMvigor130 trial and emphasizes the clinical implications of this research in metastatic urothelial cancer.
Bertrand F. Tombal, MD, PhD, explains how data on the clinically relevant drug-drug interactions and TRAEs with darolutamide, docetaxel and ADT support previously reported efficacy data from the ARASENS trial, and presents lingering questions and caveats from this trial that should be addressed through continued research.
Administration of aumolertinib until intracranial oligoprogression, followed by salvage stereotactic radiation therapy, produced central nervous system responses with acceptable tolerability in patients with intracranial oligometastatic EGFR-mutant non–small cell lung cancer.
Ryan J. Sullivan, MD, discusses previous research on tebentafusp in uveal melanoma that led to the inception of the IMCgp100-202 trial and clinical implications for data confirming the predictive value of circulating tumor DNA levels.
Balazs Halmos, MD, discusses factors to consider when selecting a biomarker assay for patients with non–small cell lung cancer, emphasizes the importance of secondary testing, provides recommendations for the treatment of patients with co-mutations, and highlights ongoing or future areas of interest for research within lung cancer.
Karen L. Reckamp, MD, MS, discusses the rationale for evaluating patients with early-stage NSCLC who received adjuvant atezolizumab as part of the LCMC3 study and explains the significance and limitations of data from a retrospective analysis.
